SciCombinator

Discover the most talked about and latest scientific content & concepts.

F Maduell, F Moreso, M Pons, R Ramos, J Mora-MaciĆ , J Carreras, J Soler, F Torres, JM Campistol and A Martinez-Castelao
Abstract
Retrospective studies suggest that online hemodiafiltration (OL-HDF) may reduce the risk of mortality compared with standard hemodialysis in patients with ESRD. We conducted a multicenter, open-label, randomized controlled trial in which we assigned 906 chronic hemodialysis patients either to continue hemodialysis (n=450) or to switch to high-efficiency postdilution OL-HDF (n=456). The primary outcome was all-cause mortality, and secondary outcomes included cardiovascular mortality, all-cause hospitalization, treatment tolerability, and laboratory data. Compared with patients who continued on hemodialysis, those assigned to OL-HDF had a 30% lower risk of all-cause mortality (hazard ratio [HR], 0.70; 95% confidence interval [95% CI], 0.53-0.92; P=0.01), a 33% lower risk of cardiovascular mortality (HR, 0.67; 95% CI, 0.44-1.02; P=0.06), and a 55% lower risk of infection-related mortality (HR, 0.45; 95% CI, 0.21-0.96; P=0.03). The estimated number needed to treat suggested that switching eight patients from hemodialysis to OL-HDF may prevent one annual death. The incidence rates of dialysis sessions complicated by hypotension and of all-cause hospitalization were lower in patients assigned to OL-HDF. In conclusion, high-efficiency postdilution OL-HDF reduces all-cause mortality compared with conventional hemodialysis.
Tweets*
16
Facebook likes*
0
Reddit*
0
News coverage*
3
Blogs*
1
SC clicks
1
Concepts
Suggestion, Outcome, Renal replacement therapy, Medical statistics, Dialysis, Randomized controlled trial, Epidemiology, Hemodialysis
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com